Does obesity and diabetes mellitus metastasize to the brain? Metaboptosis and implications for drug discovery and development

CNS Spectrums

Volumn 24, Issue 5, 2019, Pages 467-469

  McIntyre, Roger S ^a,b,c,d   Rong, Carola ^a   Mansur, Rodrigo B ^a,c   Brietzke, Elisa ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b BRAIN AND COGNITION DISCOVERY FOUNDATION   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; LIRAGLUTIDE; METFORMIN; RESVERATROL; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS;

APOPTOSIS; BIPOLAR DISORDER; CALORIC RESTRICTION; CELL AGING; CELL DEATH; CELL FRACTIONATION; COGNITION ASSESSMENT; COGNITIVE DEFECT; DEPRESSION; EDITORIAL; EPIGENETICS; EXERCISE; HEALTHY DIET; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; METABOPTOSIS; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; QUALITY OF LIFE; SLEEP HYGIENE; DIABETES MELLITUS; DRUG DEVELOPMENT; PROCEDURES; PSYCHOLOGY;

CENTRAL NERVOUS SYSTEM AGENTS; DIABETES MELLITUS; DRUG DEVELOPMENT; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY;

EID: 85063934558     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852918001670     Document Type: Editorial

References (22)

1. McIntyre RS. A vision for drug discovery and development: Novel targets and multilateral partnerships. Adv Ther. 2014; 31(3): 245-246.
2. Wen Z, Christian KM, Song H, et al. Modeling psychiatric disorders with patient-derived iPSCs. Curr Opin Neurobiol. 2016; 36: 118-127.
3. O'shea KS, McInnis MG. Neurodevelopmental origins of bipolar disorder: iPSC models. Mol Cell Neurosci. 2016; 73: 63-83.
4. Villa RF, Ferrari F, Bagini L, et al. Mitochondrial energy metabolism of rat hippocampus after treatment with the antidepressants desipramine and fluoxetine. Neuropharmacology. 2017; 121: 30-38.
5. Srivastava R, Faust T, Ramos A, et al. Dynamic changes of the mitochondria in psychiatric illnesses: New mechanistic insights from human neuronal models. Biol Psychiatry. 2018; 83: 751-760. doi: 10. 1016/j. biopsych. 2018. 01. 007.
6. Pietruczuk K, Lisowska KA, Grabowski K, et al. Proliferation and apoptosis of T lymphocytes in patients with bipolar disorder. Sci Rep. 2018; 8(1): 3327.
7. Neth BJ, Craft S. Insulin resistance and Alzheimer's disease: Bioenergetic linkages. Front Aging Neurosci. 2017; 9: 345.
8. Zheng K, Wang N, Shen Y, et al. Pro-apoptotic effects of microRNA-365 on retinal neurons by targeting IGF-1 in diabetic rats: An in vivo and in vitro study. J Diabetes Investig. 2018; 9(5): 1041-1051. doi: 10. 1111/jdi. 12815.
9. Kalaivani A, Uddandrao VS, Parim B, et al. Reversal of high fat diet-induced obesity through modulating lipid metabolic enzymes and inflammatory markers expressions in rats. Arch Physiol Biochem. 2018; 124: 1-7.
10. Mansur RB, Brietzke E, McIntyre RS. Is there a 'metabolic-mood syndrome'? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015; 52: 89-104.
11. Mansur RB, Lee Y, Zhou AJ, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Ann Clin Psychiatry. 2018; 30(1): 38-50.
12. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as 'metabolic syndrome type II'? Ann Clin Psychiatry. 2007; 19(4): 257-264.
13. Skvarc DR, Dean OM, Byrne LK, et al. The effect of N-acetylcysteine (NAC) on human cognition-A systematic review. Neurosci Biobehav Rev. 2017; 78: 44-56.
14. Sa-Nguanmoo P, Tanajak P, Kerdphoo S, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017; 333: 43-50.
15. Colle R, de Larminat D, Rotenberg S, et al. Pioglitazone could induce remission in major depression: A meta-analysis. Neuropsychiatr Dis Treat. 2017; 13: 9-16.
16. Colle R, de Larminat D, Rotenberg S, et al. PPAR-? agonists for the treatment of major depression: A review. Pharmacopsychiatry. 2017; 50(2): 49-55.
17. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012; 14(7): 697-706.
18. Craft S, Claxton A, Baker LD, et al. Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: A pilot clinical trial. J Alzheimer Dis. 2017; 57(4): 1325-1334.
19. Claxton A, Baker L, Hanson A, et al. Long-acting intranasal insulin detemir improves working memory for adults with mild cognitive impairment or early-stage Alzheimer's dementia. Alzheimers Dementia: J Alzheimers Assoc. 2013; 9(4): P657.
20. Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. J Affect Disord. 2017; 207: 114-120.
21. Mansur RB, Lee Y, Subramaniapillai M, et al. Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology. 2018; 136: 335-342. doi: 10. 1016/j. neuropharm. 2018. 01. 048.
22. Phillips AG, Geyer MA, Robbins TW. Effective use of animal models for therapeutic development in psychiatric and substance use disorders. Biol Psychiatry. 2018; 83: 915-923. doi: 10. 1016/j. biopsych. 2018. 01. 014.